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Abstract
Background and Objective Reformulated OxyContin
(oxycodone-HCl controlled release) tablets (ORF) became
available in the United States in August 2010. The original
formulation of OxyContin (oxycodone-HCl controlled
release) tablets (OC) used a delivery system that did not
provide inherent resistance to crushing and dissolving. The
objective of this study was to compare the pharmacokinetics,
tolerability, and safety of finely crushed ORF tablets, coar-
sely crushed ORF tablets, and finely crushed OC tablets.
Methods This randomized, single-blind, single-dose,
single-center, six-sequence, triple-treatment, triple-period
crossover study enrolled eligible healthy adults (aged
18–55 years inclusive). The study evaluated the pharma-
cokinetics, tolerability, and safety of intranasally admin-
istered ORF, both finely crushed and coarsely crushed, as
well as finely crushed OC tablets. Plasma oxycodone
concentrations were quantified and analyzed to determine
the maximum observed plasma concentration (Cmax), time
to maximum plasma concentration (tmax), area under the
plasma concentration–time curve from hour 0 to the last
measurable plasma concentration (AUClast), and area under
the plasma concentration–time curve extrapolated to
infinity (AUC?). The abuse quotient (AQ), calculated as
Cmax/tmax, served as an index of the average rate of increase
in drug concentration from dosing to tmax. Intranasal tol-
erability rating scales (discomfort, itching, burning, pain,
runny nose, and stuffiness) and intranasal endoscopy were
conducted. Safety assessments included adverse events,
vital signs, pulse oximetry (SpO2), and electrocardiograms.
Results Of 83 subjects screened and enrolled, 30 were
randomized to period 1, with 1 subject subsequently dis-
continuing due to the subject’s choice. Mean Cmax values for
finely crushed ORF (17.1 ng/mL) and coarsely crushed ORF
(15.5 ng/mL) were lower than that for finely crushed OC
(22.2 ng/mL). Median tmax for finely crushed OC (1.0 h)
was shorter than that for either finely crushed ORF (2.0 h) or
coarsely crushed ORF (3.0 h). Mean AQ values were
approximately 66 and 80 % lower, respectively, for finely
crushed ORF and coarsely crushed ORF than that for finely
crushed OC. Finely crushed ORF, coarsely crushed ORF,
and finely crushed OC demonstrated similar total oxycodone
exposures (AUC?). Insufflation of ORF produced greater
nasal discomfort and stuffiness than finely crushed OC,
although the latter produced higher runny nose scores. No
significant difference was found in other nasal tolerability
measures. The overall safety profile was as expected fol-
lowing opioid administration in healthy subjects.
Conclusions In contrast to OC, both finely and coarsely
crushed ORF retained some control of oxycodone release.
Reduced Cmax and increased tmax for ORF resulted in lower
AQ scores for ORF compared with OC. ORF was associ-
ated with greater intranasal irritation than OC. These data
suggest that ORF has a lower intranasal abuse potential
than OC.
1 Introduction
Opioid analgesic utilization for pain management has
increased significantly since 1998; unfortunately, along
with the increase in the legitimate use of opioid
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medications, there has also been an escalation in the abuse
of prescription opioids, particularly abuse of controlled-
release formulations that contain higher opioid content [1,
2]. Compared with substances such as cocaine and heroin,
prescription opioids are relatively easier to obtain and are
perceived as more socially acceptable to abuse. They have
also been mentioned as possible ‘‘gateway’’ drugs to other
illegal substances [3–5].
Experienced abusers and recreational users commonly
employ alternate routes of administration (e.g., injecting
and snorting) in abusing oral opioid medications [4, 6, 7].
Data suggest that the incidence of injecting oral oxycodone
products among these experienced and recreational abusers
ranges from 22 to 59 %, and the incidence of intranasal
administration ranges from 45 to 92 % [6, 7]. Abuse via
these routes first requires tampering to accelerate the
release of the active opioid, which rapidly provides a high
blood concentration compared with oral delivery [8]. To
reduce abuse and misuse, particularly by injecting and
snorting oral opioid analgesics, pharmaceutical manufac-
turers have begun to develop tamper-deterrent products [2].
Reformulated OxyContin (oxycodone-HCl controlled
release; ORF) was developed with the specific intent of
reducing abuse and misuse of the original formulation of
OxyContin (OC) without affecting legitimate use for the
management of pain. ORF tablets became available in the
United States in August 2010 at the same time that ship-
ments of OC were discontinued. OC used a delivery system
that did not provide inherent resistance to breaking,
crushing, and dissolving. ORF was designed to be orally
bioequivalent to OC, but with abuse-deterrent properties
that make abuse via nonoral routes of delivery more dif-
ficult. During formulation development, laboratory-based
tamper testing indicated that, when crushed, ORF tablets
fractionate into large pieces that discourage intranasal
abuse, and when dissolved in small amounts of aqueous
solution, the particles form a viscous solution that dis-
courages intravenous abuse [9].
This study focuses on intranasal administration of oxy-
codone, because it is associated with faster absorption than
oral administration and may therefore pose a greater risk to
the abuser [10]. Additionally, intranasal administration
involves crushing or pulverizing the tablets, which may
compromise their controlled-release properties. It was
hypothesized that upon intranasal administration, the tam-
per-deterrent properties of ORF relative to OC would
translate into a reduction in maximum observed plasma
concentration (Cmax), an increase in time to maximum
plasma concentration (tmax), and a corresponding decrease
in the abuse quotient (AQ) [6, 11, 12], suggestive of a
decrease in abuse potential.
The objective of this study was to compare the phar-
macokinetics, tolerability, and safety of finely crushed
ORF tablets, coarsely crushed ORF tablets, and finely




This was a randomized, single-blind, single-dose, single-
center, six-sequence, triple-treatment, triple-period cross-
over study designed to evaluate the pharmacokinetics,
tolerability, and safety of intranasally administered ORF,
both finely crushed (10 mg) and coarsely crushed (10 mg),
as well as finely crushed OC (10 mg). Coarsely crushed
OC was not tested because simple crushing of OC readily
produces a fine powder. To minimize variability, tampered
tablets were prepared using standardized equipment and
techniques.
Study duration was up to 42 days; a 28-day screening
phase was followed by a 7-day treatment phase, with fol-
low-up 3–7 days after the last dose of study drug. The
treatment phase was divided into three periods (days 1–3,
3–5, and 5–7). The assignment of subjects to treatment
sequence was single-blinded. Efforts were made to prevent
subjects from making side-by-side comparisons of study
drugs, which were similar, but not identical, in appearance.
This study protocol and its informed consent form was
submitted to the Western Institutional Review Board (IRB)
for review and approval. It was conducted in accordance
with regulatory guidelines and the applicable International
Conference on Harmonization guidelines of Good Clinical
Practice, as consistent with the Declaration of Helsinki. All
subjects provided oral and written consent before conduct
of any protocol-related procedures. Subjects were informed
that they could discontinue the study at any time.
2.2 Subjects
Subjects were healthy men and women (aged 18–55 years
inclusive) with no clinically significant medical history or
any other concerns that would have jeopardized the study’s
safety or validity, as determined by the principal investi-
gator. Special preference for study enrollment was given to
recreational drug users who had experience with opioid use
on at least five occasions, and to subjects who reported at
least three occasions of intranasal opioid use for the pur-
pose of abuse/misuse within the past year. Subjects were
excluded if they had significant obstruction of either naris,
or clinically important changes in the intranasal cavity that
would interfere with the study procedures or data integrity
or compromised the safety of the subject. Subjects with
piercings through the nose or a perforated nasal septum
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were given a lower priority than those without these
findings.
Other conditions warranting exclusion from participation
were use of any medication/herbal product [except paracet-
amol (acetaminophen) (2 g/day), vitamin or mineral sup-
plements, birth control, and hormone replacement] within
7 days of study drug administration or for the study duration.
2.3 Treatment
A physical examination, biochemistry tests, and urinalysis
were conducted for each subject at screening. Subjects
abstained from consuming alcoholic beverages for 48 h
prior to initial study drug administration (day 1) and for the
duration of the study (i.e., through to the end of study
procedures). They were confined to a nonsmoking study
facility the day prior to administration of the study drug
and throughout all three periods of the study. Subjects
abstained from caffeine or xanthine entirely during con-
finement. While confined at the study site, they received
meals at scheduled times that did not conflict with other
study-related activities. The same standard meal timing
was employed over corresponding study days in each
period, but the content of meals varied.
Subjects were randomized to a treatment sequence on
the morning of day 1 and received treatments on days 1, 3,
and 5 of the treatment phase, with a minimum washout
period of 48 h between dose administrations. For each
treatment period, subjects completed a 10-h overnight fast
before sitting in an upright position and intranasally in-
sufflating a dose of finely crushed ORF (10 mg), coarsely
crushed ORF (10 mg), or finely crushed OC (10 mg)
through a short thin straw. Dosing was carefully observed
by the site staff, and the weight of any drug not success-
fully insufflated during the 5-min administration period
was recorded, with significant amounts of nonadministered
drug potentially resulting in subject discontinuation from
the study. Subjects continued fasting for 4 h subsequent to
dosing and were to remain upright, unless a procedure
required that they be in the supine position. They remained
confined to the study site throughout all three treatment
periods and abstained from strenuous exercise or physical
exertion. Treatment procedures were identical for all three
treatment periods, with subjects receiving single intranasal
doses of study drug in alternating nares (e.g., left-right-
left). Telephone follow-ups were conducted 3–7 days after
the last dose or following early discontinuation.
2.4 Pharmacokinetic Measures
During each treatment period, blood samples for deter-
mining oxycodone plasma concentrations were obtained
for each subject just prior to dosing and at 0.25, 0.5, 0.75,
1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10, 12, 16, 24,
28, 32, 36, and 48 h postdose. For each sample, venous
blood (4 mL) was drawn via an indwelling catheter or
direct venipuncture into tubes containing potassium ethy-
lenediaminetetraacetic acid anticoagulant. A validated
liquid chromatography tandem mass spectrometric method
quantified plasma concentrations of oxycodone (lower
limit of quantitation was 0.1 ng/mL).
Relative bioavailability was determined by comparison to
the reference treatment (finely crushed OC). Pharmacokinetic
metrics were calculated, whenever possible, based on the
plasma concentrations of oxycodone according to the model
independent approach. Pharmacokinetic calculations were
performed using WinNonLin (Pharsight Corporation, St.
Louis, MO, USA; Version 5.2). Noncompartmental analysis
of plasma oxycodone concentrations generated values for:
maximum observed plasma concentration (Cmax), time to
maximum plasma concentration (tmax), area under the plasma
concentration–time curve from hour 0 to the last measurable
plasma concentration (AUClast), area under the plasma con-
centration–time curve extrapolated to infinity (AUC?), and
half-life (t1/2). These pharmacokinetic metrics permit
assessment of the rate and extent of drug absorption (bio-
availability). AUC? is an index of total drug exposure and
Cmax is an index of maximum or peak exposure to treatment.
The AQ, calculated as Cmax/tmax, is a measure of the average
rate of rise in concentration between dosing and tmax [12].
Because more rapid exposure to higher opioid concentrations
correlates with greater drug-liking, higher AQ scores predict
greater abuse potential [6, 11, 12].
2.5 Intranasal Tolerability
Pharmacodynamic measurements were assessed by evalu-
ating intranasal tolerability. Subjects rated intranasal dis-
comfort, itching, burning, pain, runny nose, and stuffiness
on numeric scales ranging from 0 (none) to 10 (worst I can
imagine). Ratings measured only the naris used for drug
administration. Intranasal tolerability rating scales were
evaluated at predose and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0,
2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10, and 12 h postdose. At
approximately 5 and 24 h after each dosing, subjects pro-
vided a written response to the question, ‘‘What effects (if
any) did snorting this drug cause to the inside of your
nose?’’ Additionally, a specialist in ear, nose, and throat
procedures performed intranasal endoscopies. These were
conducted at predose, and as close to 0.5 h postdose as
possible, but not later than 2 h postdose.
2.6 Safety Measures
Safety assessments included reports of adverse events
(AEs), clinical laboratory test results, vital signs results,
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pulse oximetry (SpO2), physical examinations, and elec-
trocardiograms (ECGs). Reported AEs were coded
according to the Medical Dictionary for Regulatory
Activities (version 9.1) by preferred term and system organ
class. AEs reported herein are those that emerged, ree-
merged, and/or worsened in severity during treatment and
were classified as treatment-emergent AEs.
2.7 Statistical Analysis
Subjects who were randomized, received study drug, and
had at least one postdose safety assessment were included
in safety analyses; subjects who were randomized, received
study drug, and had at least one valid pharmacokinetic
metric were included in pharmacokinetic analyses. For
pharmacokinetic data, a mixed-model analysis of variance
was used to compare logarithmic-transformed (base e)
values for Cmax, AUClast, and AUC? of oxycodone, with
fixed effects for treatment, period, and sequence, as well as
random effects of subject within sequence.
For pharmacokinetic data, bioequivalence was indicated
if the 90 % confidence intervals (CIs) for oxycodone for a
given measure fell entirely within the 80–125 % range.
Intranasal tolerability rating scales used descriptive statis-
tics for raw data and for differences from predose for each
time point and treatment. The maximum response over
time was tabulated and an analysis of covariance model
was conducted to assess differences among treatments
related to maximum response. This pharmacodynamic
model included a covariate for the predose assessment,
fixed effects for treatment, period, and sequence, and a
random effect of the subject within sequence.
3 Results
Of 83 subjects screened and enrolled, 30 were randomized
(Fig. 1). One was discontinued in period 1 due to the sub-
ject’s choice, leaving 29 in treatment periods 2 and 3. The
mean (range) age of subjects was 32 (19–52) years. Of the
randomized subjects, most were male (66.7 %) and most
were white (83.3 %). Mean (range) body weight, height, and
body mass index were 78.1 (49.9–94.0) kg, 171.5
(156.0–187.0) cm, and 26.5 (19.1–31.9) kg/m2, respectively.
3.1 Pharmacokinetics
After intranasal administration, mean Cmax was lower for
finely crushed ORF and coarsely crushed ORF than that for
finely crushed OC (Table 1; Fig. 2). The mean Cmax metric
ratio comparing coarsely crushed ORF and finely crushed
OC indicated a 33 % lower Cmax for coarsely crushed ORF
(Table 2). The mean Cmax metric ratio comparing finely
crushed ORF and finely crushed OC indicated a 22 %
lower Cmax for finely crushed ORF. In addition, median
tmax values were reached more rapidly for finely crushed
OC than for either finely crushed ORF or coarsely crushed
ORF (Table 1; Fig. 2). The highest mean AQ score was
observed for finely crushed OC (31.7 ng/mL per h) com-
pared with either ORF preparation (Fig. 3), with mean AQ
scores for finely crushed ORF and coarsely crushed ORF
approximately 66 and 80 % lower, respectively, versus
finely crushed OC.
After intranasal administration, mean oxycodone AUC?
values were 124, 134, and 128 ngh/mL for finely crushed
ORF, coarsely crushed ORF, and finely crushed OC,
respectively (Table 1). Mean metric ratios between finely
crushed ORF, coarsely crushed ORF, and finely crushed
OC are illustrated in Table 2. With mean metric ratios
falling within the 80–125 % CI range for all treatment
comparisons, these results indicated comparability of















ORF-F 10 mg: n=10
ORF-C 10 mg: n=10
OC-F 10 mg: n=10
Period 2
n=29
ORF-F 10 mg: n=10
ORF-C 10 mg: n=9
OC-F 10 mg: n=10
Period 3
n=29
ORF-F 10 mg: n=9
ORF-C 10 mg: n=10
OC-F 10 mg: n=10
Fig. 1 Study disposition. OC-F finely crushed original formulation
of oxycodone-HCl controlled release, ORF-C coarsely crushed
reformulated oxycodone-HCl controlled release, ORF-F finely
crushed reformulated oxycodone-HCl controlled release
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3.2 Intranasal Tolerability
Compared with finely crushed OC, insufflation of finely
crushed ORF and coarsely crushed ORF produced signifi-
cantly higher mean ratings of nasal discomfort (P = 0.0030
and P \ 0.0001, respectively) and intranasal stuffiness
(P \ 0.0001 for each) (Fig. 4). Insufflation of finely cru-
shed ORF produced a significantly lower mean rating for
runny nose than finely crushed OC (P = 0.0363), and
coarsely crushed ORF yielded significantly greater intra-
nasal discomfort than finely crushed ORF (P = 0.0106).
There were no significant differences noted for other mea-
sures of nasal tolerability (burning, itching, or pain).
Intranasal endoscopy at 0.5 h after insufflation of either
ORF preparation revealed a coarse, white, gel-foam-type
material in the nasal passages of subjects, whereas nasal
passages were clear after insufflation of finely crushed OC.
Subject comments corroborated these findings (see repre-
sentative data in Fig. 5).
3.3 Safety
No deaths or serious adverse events were reported. Of the
93 AEs reported, 25 were reported in 15 subjects with
finely crushed ORF, 29 were reported in 12 subjects with
coarsely crushed ORF, and 39 were reported in 9 subjects
with finely crushed OC. One subject chose to discontinue
from the study due to an AE of nausea with finely crushed
OC (10 mg) dosing. The most commonly reported AEs
were headache, nausea, and vomiting and most AEs were
of mild or moderate severity. The number and percentage
of distinct subjects with AEs that were judged to be related
to study treatment are shown in Table 3. All AEs resolved
by study end. The eight AEs that were severe and related to
treatment were vomiting (3), nausea (3), headache (1), and
pain in extremity (1); these were reported by four subjects.
Results of laboratory tests, vital signs measurements, SpO2
evaluations, and ECG recordings revealed no clinically
significant abnormalities and raised no safety concerns for
the study treatments.
4 Discussion
This study compared the effects of original OxyContin
(OC) and reformulated OxyContin (ORF) on the
pharmacokinetic, pharmacodynamic, and safety profiles
of healthy men and women. ORF, with its abuse-
deterrent properties of reduced crushability showed the
intended effects of reduced Cmax, delayed tmax, reduced
AQ, and significantly increased intranasal intolerability
compared with OC. The safety profile of ORF was
similar to that of OC. Most AEs for all treatments were
classified as mild or moderate and were those commonly
associated with opioid use (e.g., nausea, vomiting, and
headache).
Subjects reported greater intranasal discomfort, stuffi-
ness, and intranasal obstruction with ORF than with OC.
Decreased subject-reported tolerability and visual demon-
strations of increased deposition of undissolved, crushed
ORF suggest that recreational abusers, intent on using
intranasal administration of prescription opioids, may find
that ORF has low desirability. The current study examines
acute tolerability of a single-dose administration, so the
Table 1 Mean oxycodone pharmacokinetic metrics (full analysis population)
Parameter ORF-F 10 mg (n = 29) ORF-C 10 mg (n = 29) OC-F 10 mg (n = 30)
Cmax (ng/mL) Mean (SD) 17.1 (3.65) 15.5 (5.41) 22.2 (4.87)
AUC? (ngh/mL) Mean (SD) 124 (29.3) 134 (45.1) 128 (29.4)
AUClast (ngh/mL) Mean (SD) 123 (29.2) 133 (45.0) 127 (29.4)
tmax (h) Median (range) 2.00 (0.75–3.50) 3.00 (1.00–8.13) 1.00 (0.25–2.50)
t1/2 (h) Mean (SD) 4.43 (0.786) 4.45 (0.796) 4.46 (0.810)
AUC? area under the plasma concentration–time curve extrapolated to infinity, AUClast area under the plasma concentration–time curve from
hour 0 to the last measurable plasma concentration, Cmax maximum observed plasma concentration, OC-F finely crushed original formulation of
oxycodone-HCl controlled release, ORF-C coarsely crushed reformulated oxycodone-HCl controlled release, ORF-F finely crushed reformulated































L) ORF-F 10 mg (n=29)
OC-F 10 mg (n=30)
ORF-C 10 mg (n=29)
Time postdose (h)
0 4 8 12 16 20 24 48
Fig. 2 Mean plasma oxycodone concentrations following intranasal
dosing over time in the full analysis set. OC-F finely crushed original
formulation of oxycodone-HCl controlled release, ORF-C coarsely
crushed reformulated oxycodone-HCl controlled release, ORF-F
finely crushed reformulated oxycodone-HCl controlled release
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impact of chronic intranasal abuse of ORF cannot be
determined. However, medical complications involving the
nasal mucosa with chronic intranasal substance abuse have
been documented [13–15].
This study focused on OxyContin abuse via the intra-
nasal route of administration (i.e., snorting), which is a
commonly used method of abuse [7]. OC can be easily
crushed to disable its controlled-release properties [6, 8, 16,
17]. The pharmacokinetic profile of orally administered,
crushed OC has been shown to be similar to that of
immediate-release oxycodone [18]. In addition, intranasal
administration of crushed OC resulted in rapid absorption,
with most (approximately 75 %) of the administered dose
being absorbed, indicating that intranasal administration
after crushing is an efficient means of defeating the con-
trolled-release properties of original OxyContin [8]. This
is not unexpected given evidence showing the nasal mucosa
is an efficient absorptive surface for agents delivered in
powdered form [19, 20]. The rapid rate of absorption that
occurs with intranasal nonmedical administration of opioids
may increase their abuse potential. Furthermore, recent
findings suggest that rate of infusion of opioids, including
intravenous morphine [21] and oxycodone [22], is an
important determinant of the reinforcing effects of these
agents, with rapid infusion resulting in greater effects.
The ultimate goal of the development of ORF was to
replace a readily abusable product with an abuse-deterrent
product that reduced the frequency and adverse consequences
of abuse while maintaining access to treatment for patients
with moderate to severe pain who require a continuous,
around-the-clock opioid analgesic for an extended period of
time. Although no opioid product can ever be abuse-proof [1,
2], abuse-deterrent products offer the possibility of incre-
mental or more substantial reductions in abuse potential
compared with previously developed products that are more
easily altered, depending upon the product/formulation, the
route, the tampering method, and the population [2].
The current study, illustrating the differences in phar-
macokinetic profile of intranasal administration of OC and
ORF, includes elements that have been recommended for
assessing the pharmacokinetic profile of an abuse-deterrent
product [3, 23]. Pharmacokinetic and safety analyses are
one of four critical components used to characterize the
abuse potential of ORF. The other components consist of
in vitro tamper-testing studies conducted during formula-
tion development [9], abuse-liking studies [24, 25], and,
lastly, epidemiological studies. The real-world impact of
any abuse-deterrent product needs to be established by a
variety of epidemiologic studies conducted in real-world
settings [1–3, 11, 12]. Those epidemiologic studies are
currently in progress for reformulated OxyContin [26].
Recently reported findings appear to support the labora-
tory-based tamper-testing and abuse potential studies for
ORF, including decreased rates of self-reported nonoral
abuse in a large national interview survey database [27];
decreased rates of intranasal abuse in a cohort of Oxy-
Contin abusers in rural Kentucky [28]; and decreased
incidence of diversion and a decrease in reported street
value in surveys from law enforcement agencies [29, 30].
Table 2 Treatment comparisons of pharmacokinetic metrics
Parameter ORF-C vs ORF-F ORF-F vs OC-F ORF-C vs OC-F
Cmax (ng/mL) Mean ratio of PK metric (90 % CI) 86.3 (76.91, 96.78) 77.6 (69.27, 87.02) 67.0 (59.76, 75.07)
AUC? (ngh/mL) Mean ratio of PK metric (90 % CI) 103.0 (91.64, 116.10) 97.4 (86.56, 109.50) 100.0 (89.29, 112.94)
Treatment groups were ORF-C 10 mg (n = 29), ORF-F (n = 29), and OC-F 10 mg (n = 30)
AUC? area under the plasma concentration-time curve extrapolated to infinity; CI confidence interval, Cmax maximum observed plasma
concentration, OC-F finely crushed original formulation of oxycodone HCl controlled release, ORF-C coarsely crushed reformulated oxycodone








































ng/mL/h [mean (SD)] 
Parameter
31.7 (25.90)6.4 (4.54)
Fig. 3 Abuse quotient box and whisker plots. The open circles
represent the individual abuse quotient values for each patient. Cmax
maximum observed plasma concentration, OC-F finely crushed
original formulation of oxycodone-HCl controlled release, ORF-C
coarsely crushed reformulated oxycodone-HCl controlled release,
ORF-F finely crushed reformulated oxycodone-HCl controlled release,
SD standard deviation, tmax time to maximum plasma concentration
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Fig. 4 Comparison of maximum response over time on the Intranasal
Tolerability Rating Scale (ITRSa) in the randomized safety popula-
tion. aITRS was rated on an 11-point scale, ranging from 0 (none) to
10 (worst I can imagine). bLS means from ANCOVA. cDifference of
means between treatments from ANCOVA. d90 % CI for difference
of means from ANCOVA. eP value for pairwise comparison between
treatments from ANCOVA. *P \ 0.05 between treatment groups.
ANCOVA analysis of covariance, CI confidence interval, ITRS
Intranasal Tolerability Rating Scale: ITRS was rated on an 11-point
scale, ranging from 0 (none) to 10 (worst I can imagine), LS least
squares, OC-F finely crushed original formulation of oxycodone-HCl
controlled release, ORF-C coarsely crushed reformulated oxycodone-
HCl controlled release, ORF-F finely crushed reformulated oxyco-
done-HCl controlled release
Fig. 5 Representative intranasal endoscopy results. OC-F finely crushed original formulation of oxycodone-HCl controlled release, ORF-C
coarsely crushed reformulated oxycodone-HCl controlled release, ORF-F finely crushed reformulated oxycodone-HCl controlled release
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One limitation of the present study is that statistical
significance testing using P values was not done. Another
limitation is that the endpoints were for pharmacokinetics
and safety only, and standardized measures of ‘‘drug lik-
ing’’ were not incorporated. The results of the present study
can be more clearly interpreted in light of subsequent
research looking at both pharmacokinetics and the phar-
macodynamics of drug liking.
In January 2013, the US Food and Drug Administration
(FDA) released its guidance, Abuse-Deterrence Opioids—
Evaluation and Labeling [31]. This guidance proposes that
summary statements and label claims regarding abuse
deterrence can be based on pharmacokinetic data. The
present study employed the major design elements rec-
ommended by the FDA in this guidance: the use of the
most common route of administration for abuse, the impact
of food and alcohol taken into consideration in the design
of the study, the measurement of the rate of rise of drug
concentration, the inclusion of relevant pharmacokinetic
parameters, and the documenting of AEs.
5 Conclusions
In contrast to the original formulation, reformulated Oxy-
Contin administered intranasally demonstrated a lower
Cmax, a longer tmax, and a lower AQ when compared with
the original formulation. Crushed reformulated OxyCon-
tin was also associated with greater intranasal irritation
than crushed original OxyContin, with otherwise similar
safety profiles. Overall, these data suggest that reformu-
lated OxyContin has a reduced abuse potential compared
to the original formulation upon intranasal administration.
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